TMCnet News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on July 1, 2020, the compensation committee of BridgeBio’s board of directors granted eight employees options to purchase an aggregate of 7,120 shares of the Company’s common stock with a per share exercise price of $30.34 and restricted stock units for an aggregate of 15,134 shares of the Company’s common stock, including 1,610 performance-related restricted stock units. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employes entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019. About BridgeBio Media Contact: Investor Contact: Source: BridgeBio Pharma, Inc. |